SUS Stock Overview
Develops and markets virtual reality simulators for evidence-based medical training in Europe, North and South America, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SUS from our risk checks.
Surgical Science Sweden AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 146.10 |
| 52 Week High | SEK 196.90 |
| 52 Week Low | SEK 111.80 |
| Beta | 0.97 |
| 11 Month Change | 16.14% |
| 3 Month Change | 12.82% |
| 1 Year Change | -11.72% |
| 33 Year Change | -50.64% |
| 5 Year Change | 90.23% |
| Change since IPO | 1,170.43% |
Recent News & Updates
The Price Is Right For Surgical Science Sweden AB (publ) (STO:SUS)
Nov 12
Surgical Science Sweden AB (publ) Just Missed EPS By 22%: Here's What Analysts Think Will Happen Next
Aug 25Recent updates
The Price Is Right For Surgical Science Sweden AB (publ) (STO:SUS)
Nov 12Surgical Science Sweden AB (publ) Just Missed EPS By 22%: Here's What Analysts Think Will Happen Next
Aug 25Earnings Beat: Surgical Science Sweden AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 21Here's Why Surgical Science Sweden (STO:SUS) Has Caught The Eye Of Investors
Apr 16Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Mar 17Results: Surgical Science Sweden AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 24Is There Now An Opportunity In Surgical Science Sweden AB (publ) (STO:SUS)?
Nov 29Should You Be Adding Surgical Science Sweden (STO:SUS) To Your Watchlist Today?
Oct 07Is Surgical Science Sweden AB (publ) (STO:SUS) Trading At A 39% Discount?
Aug 17With EPS Growth And More, Surgical Science Sweden (STO:SUS) Makes An Interesting Case
Jun 20A Look At The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
May 17Surgical Science Sweden AB (publ) (STO:SUS) Shares Could Be 49% Below Their Intrinsic Value Estimate
Dec 27Is Now The Time To Put Surgical Science Sweden (STO:SUS) On Your Watchlist?
Dec 06Is Now The Time To Look At Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Sep 08We Ran A Stock Scan For Earnings Growth And Surgical Science Sweden (STO:SUS) Passed With Ease
Aug 23Surgical Science Sweden AB (publ) (STO:SUS) Shares Slammed 33% But Getting In Cheap Might Be Difficult Regardless
May 26Here's Why We Think Surgical Science Sweden (STO:SUS) Is Well Worth Watching
Apr 29An Intrinsic Calculation For Surgical Science Sweden AB (publ) (STO:SUS) Suggests It's 44% Undervalued
Feb 20Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jan 11Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Dec 15Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Sep 16Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jul 05Calculating The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Jun 08Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Mar 23Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Mar 02Is Surgical Science Sweden AB (publ)'s (STO:SUS) Shareholder Ownership Skewed Towards Insiders?
Feb 09
Surgical Science Sweden AB (publ)'s (STO:SUS) Stock Is Going Strong: Have Financials A Role To Play?
Jan 01What Does Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Indicate?
Dec 14Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Nov 26Shareholder Returns
| SUS | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 5.5% | -4.1% | -2.1% |
| 1Y | -11.7% | -9.7% | 10.8% |
Return vs Industry: SUS underperformed the Swedish Medical Equipment industry which returned -9.7% over the past year.
Return vs Market: SUS underperformed the Swedish Market which returned 10.8% over the past year.
Price Volatility
| SUS volatility | |
|---|---|
| SUS Average Weekly Movement | 6.9% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: SUS has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: SUS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 265 | Tom Englund | www.surgicalscience.com |
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnostic and therapeutic hysteroscopy training; URO Mentor, a virtual reality simulator for endourology training; EndoSim, a realistic scope simulator; FlexVR, a flexible and portable training platform which is designed to teach basic and advanced skills for robotic surgery; and LAP Mentor provides a wide array of laparoscopic training cases. It also provides LapSim training system comprising LapSim Haptic simulator provides laparoscopic training; LapSim essence, a portable and ready-to-use VR simulator; and LapSim 360, which provides high-immersion virtual reality training experience; MentorLearn, an end-to-end educational platform that makes simulation course management; and LapSim ST, a state-of-the-art training system that prepares students for the operating room.
Surgical Science Sweden AB (publ) Fundamentals Summary
| SUS fundamental statistics | |
|---|---|
| Market cap | SEK 7.25b |
| Earnings (TTM) | SEK 193.34m |
| Revenue (TTM) | SEK 859.83m |
38.6x
P/E Ratio8.7x
P/S RatioIs SUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUS income statement (TTM) | |
|---|---|
| Revenue | SEK 859.83m |
| Cost of Revenue | SEK 269.58m |
| Gross Profit | SEK 590.25m |
| Other Expenses | SEK 396.91m |
| Earnings | SEK 193.34m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 19, 2025
| Earnings per share (EPS) | 3.79 |
| Gross Margin | 68.65% |
| Net Profit Margin | 22.49% |
| Debt/Equity Ratio | 0% |
How did SUS perform over the long term?
See historical performance and comparison